Trial ID or NCT#
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
- - Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI. - Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia. - Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
- -Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToMei-Sze Chua
Go Back To The Trial